Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Learn how to get Zepbound online, in-person, and through the drug’s manufacturer, Eli Lilly, directly. Share on Pinterest Zepbound is a dual glucose-dependent insulinotropic polypeptide (GIP ...

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...

The U.S. Food and Drug Administration ordered a hold on a study of an early-stage obesity drug being developed by Amgen, another potential setback in the company’s efforts to join the booming weight ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

More than 69.2 million FDA-approved weight-loss prescriptions were dispensed in the U.S. from July 2017 through February 2024 ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug ...